EN | TR
E-ISSN: 3061-9947
Thrombin activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI), and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer
PDF
Cite
Share
Request
Original Article
VOLUME: 49 ISSUE: 1
P: 6-12
2016

Thrombin activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI), and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer

Acta Haematol Oncol Turc 2016;49(1):6-12
DOI: 10.5505/aot.2016.22932
Tarık Salman
Leyla Demir
Çağatay Arslan
Mazit Koldaş
Umut Varol
Utku Oflazoğlu
Yüksel Küçükzeybek
Ahmet Alacacıoğlu
Uğur Yılmaz
1. Department of Medical Oncology İzmir Katip Celebi University Faculty of Medicine, İzmir, Turkey
2. Departmant of Biochemistry, İzmir Katip Celebi University Faculty of Medicine, İzmir, Turkey
3. Department of Medical Oncology İzmir University Medikal Park Hospital, İzmir, Turkey
4. Department of Biochemistryi Haseki Atatürk Research And Training Hospital, İzmir, Turkey
5.
No information available.
No information available
Received Date: 2015-11-11T22:33:05
Accepted Date: 2016-03-01T17:09:58
PDF
Cite
Share
Request

Abstract

INTRODUCTION

Thromboembolism is common in cancer patients. During colorectal cancer development and progression, many molecules located in coagulation and fibrinolytic systems are activated. Thrombin activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI) and prothrombin fragment 1+2 (F1+2) are newly identified molecules involved in coagulation and fibrinolysis. The aim of this study was to investigate the relationship between clinicopathologic characteristics and TAFI, TFPI and F1+2 levels in patients with advanced colorectal.

METHODS

Eighty-two patients (32 metastatic, 50 locally advanced disease) diagnosed with colorectal cancer in the medical oncology clinic. Serum TAFI, TFPI, and prothrombin F1+2 levels were evaluated via enzyme-linked immunosorbent assay. Clinicopathologic characteristics of the patients were investigated retrospectively from the medical records of the patients.

RESULTS

There were 28 (34%) females and 54 males (66%) included in the study. The mean age of the participants was 56 years. The plasma TAFI, TFPI, and prothrombin F1+2 levels were high in 70, 71, and 96% of the patients, respectively. Prothrombin F1+2 levels were higher among patients with lower performance scores. TFPI levels were higher among patients with tumor grades of 2 and 3. TAFI levels were higher among rectal cancer cases. Age, gender, BMI, metastatic or locally advanced disease, size of tumor, vascular invasion, perineural invasion, carcinoembryonic antigen, hemoglobin and thrombocyte levels were not associated with TAFI, TFPI, and prothrombin F 1+2 levels

DISCUSSION AND CONCLUSION

Higher TFPI levels in case of tumors at higher stages can indicate that there is an association between tumor grade and coagulation cascade. The higher prothrombin F1+2 levels, an indicator of active coagulation cascade, among patients with low performance scores may indicate that the coagulation cascade of these patients is more active. Higher TAFI levels among rectal cancer patients may be related to the natural course of the disease.